Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Expected to Announce Quarterly Sales of $910.92 Million

Brokerages expect Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) to post $910.92 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Jazz Pharmaceuticals’ earnings. The highest sales estimate is $925.75 million and the lowest is $882.00 million. Jazz Pharmaceuticals reported sales of $751.81 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 21.2%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year sales of $3.59 billion for the current financial year, with estimates ranging from $3.53 billion to $3.70 billion. For the next fiscal year, analysts expect that the business will post sales of $3.75 billion, with estimates ranging from $3.49 billion to $4.21 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The specialty pharmaceutical company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.13. The company had revenue of $813.72 million during the quarter, compared to analysts’ expectations of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 13.63% and a positive return on equity of 22.45%. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.42 EPS.

JAZZ has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 26th. Cowen lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a report on Thursday, May 5th. Needham & Company LLC restated a “buy” rating and set a $215.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, February 7th. Piper Sandler reduced their target price on shares of Jazz Pharmaceuticals from $197.00 to $193.00 in a report on Thursday, May 5th. Finally, Cowen increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research report on Thursday, May 5th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Buy” and an average target price of $206.47.

Shares of NASDAQ JAZZ opened at $148.53 on Monday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.06 and a current ratio of 3.39. The company has a market capitalization of $9.26 billion, a PE ratio of -19.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.79. Jazz Pharmaceuticals has a 1 year low of $117.64 and a 1 year high of $189.00. The company’s fifty day moving average price is $157.79 and its 200 day moving average price is $143.38.

In other news, CEO Bruce C. Cozadd sold 10,772 shares of the stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $158.33, for a total transaction of $1,705,530.76. Following the transaction, the chief executive officer now directly owns 346,062 shares in the company, valued at approximately $54,791,996.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 7,260 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $156.63, for a total value of $1,137,133.80. Following the completion of the sale, the chief executive officer now owns 348,502 shares of the company’s stock, valued at approximately $54,585,868.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,330 shares of company stock valued at $3,483,255. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Private Capital Group LLC grew its stake in shares of Jazz Pharmaceuticals by 1,975.0% during the first quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 158 shares during the last quarter. Lloyd Advisory Services LLC. acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $29,000. Quent Capital LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $31,000. National Bank of Canada FI purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth about $35,000. Finally, Elequin Capital LP purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $42,000. 93.23% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Recommended Stories

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.